San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University and Childr ...

San Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases, today announced the presentation of interim data from its Phase 2 (EU) clinical study of TTI-0102 in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) at Mitocon 2026 - a leadi ...

COMPANY OVERVIEW January 2026 Forward-Looking Statements This presentation includes certain statements that are deemed to be forward-looking statements. Generally, the use of words such as "may," "see," "expectation," "expect," "intend," "estimate," "projects," "anticipate," "believe," "assume," "could," "should," "plans," "targets" or similar expressions that convey the uncertainty of future events, activities, expectations or outcomes identify forward-looking statements that the Company intends to be incl ...

TETRA Technologies (NYSE:TTI) FY Conference Summary Company Overview - TETRA Technologies is currently on a run rate of approximately $600 million in revenue and over $100 million in EBITDA, with EBITDA margins steadily increasing over the years, reaching 33% recently [1][3] - The company has divested from compression, offshore oil and gas, and decommissioning businesses to focus on water and flowback services and industrial chemicals in offshore oil and gas completion fluids [2] Financial Performance - Revenue for the trailing 12 months ended September was $362 million, the highest in a decade [3] - EBITDA margins have historically been in the mid- to high 20s, with a recent increase to 33% due to significant deep water wells completed in the Gulf of Mexico [3] - The calcium chloride business generated about $160 million in revenue with 30% EBITDA margins, which is not correlated to oil and gas [3] Strategic Focus and Growth Initiatives - TETRA is transitioning into sectors with higher growth opportunities beyond oil and gas, including battery storage and water treatment [5][14] - The company has seen a significant ramp-up in sales of a zinc bromide-based solution to EOS, increasing from $3 million in 2024 to approximately $20 million in 2025, with expectations of $50-$60 million in 2026 [5][6] - TETRA is developing technologies for water desalination and purification, targeting applications in crop irrigation and data center cooling [6][22] Market Dynamics and Competitive Position - TETRA is expanding its operations to extract bromine from the Smackover Formation in Arkansas to meet increasing demand from EOS and the offshore oil and gas market [7][27] - The company competes with larger firms like Schlumberger, Halliburton, and Baker Hughes, but maintains a market share of up to 30% due to its vertically integrated business model and unique chemistry know-how [11] Future Projections - TETRA aims to grow revenue from $600 million to $1.25 billion and EBITDA from over $100 million to about $325 million by 2030, with a balanced revenue mix from oil and gas, water treatment, and specialty chemicals [13][14] - The company plans to treat 500,000 barrels of produced water per day by 2030, translating to over $400 million in revenue and over $100 million in EBITDA [35] Operational Insights - TETRA's water treatment model involves cleaning produced water for beneficial reuse, with a focus on meeting the specifications required for data center operations [22][40] - The company has a solid balance sheet with a leverage ratio of 1.2 times and $50-$60 million in cash, positioning it well for future investments [28][29] Conclusion - TETRA Technologies is strategically repositioning itself to capitalize on high-growth markets in battery storage and water treatment while maintaining strong margins in its traditional oil and gas business, which is expected to create significant shareholder value [29][50]

Core Insights - Thiogenesis Therapeutics, a clinical-stage biotechnology company, announced that an abstract of preliminary results from its Phase 2 clinical trial of TTI-0102 for MELAS has been accepted for presentation at the Mitocon Conference 2026 [1][2] Company Overview - Thiogenesis Therapeutics is focused on developing next-generation sulfur-based prodrugs aimed at treating rare mitochondrial and metabolic diseases [1][9] - The company is publicly traded on the TSX Venture Exchange and OTCQX, with operations based in San Diego, California [9] Clinical Trial Details - The Phase 2 MELAS clinical trial is a randomized, double-blind, placebo-controlled, multi-center study assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of oral TTI-0102 in patients with MELAS [3] - Interim results have shown biological proof-of-concept and biomarker activity supporting TTI-0102's mechanism of action [3] Presentation at Mitocon Conference - The poster titled "Pharmacokinetics and Pharmacodynamics of TTI-0102 in MELAS" will be presented on January 23, summarizing preliminary findings from the Phase 2 MELAS study [2] - The selection for a late-breaking presentation highlights the scientific importance of the data generated in the study [4] Product Information - TTI-0102 is designed to overcome limitations of first-generation thiol therapies, offering improved tolerability and once-daily dosing [8] - The product candidate is being evaluated for multiple indications related to mitochondrial dysfunction and oxidative stress [8] Related Conditions - MELAS is an inherited mitochondrial disorder with an estimated prevalence of approximately 4.1 per 100,000 people worldwide [6] - Leigh syndrome spectrum, another condition being targeted by Thiogenesis, affects an estimated 1 in 40,000 live births and currently has no approved treatments [7]

Core Insights - Thiogenesis Therapeutics, a clinical-stage biotechnology company, is focused on developing sulfur-based prodrugs for rare mitochondrial and metabolic diseases, with its CEO participating in a significant webinar to discuss clinical updates on their lead product candidate, TTI-0102 [1][2]. Company Overview - Thiogenesis Therapeutics, Corp. is publicly traded on the TSX Venture Exchange and OTCQX, based in San Diego, California, and specializes in sulfur-containing prodrugs aimed at treating serious pediatric diseases with unmet medical needs [7]. Clinical Programs - The company is advancing its lead product candidate, TTI-0102, which is designed to address mitochondrial oxidative stress, a key pathological feature of inherited mitochondrial disorders, with no approved therapies currently available [2][6]. - TTI-0102 is undergoing a Phase 2 clinical trial for Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) and plans to initiate a Phase 2a clinical trial for Leigh syndrome spectrum (LSS) in the U.S. [2][7]. Disease Context - MELAS is an inherited mitochondrial disorder affecting approximately 4.1 per 100,000 of the population globally, characterized by symptoms such as seizures and muscle weakness [4]. - Leigh syndrome spectrum is a rare genetic disease diagnosed in about 1 in 40,000 live births, with symptoms including poor muscle development and respiratory issues, and currently has no approved drugs [5]. Product Details - TTI-0102 is a next-generation cysteamine-based prodrug that aims to improve tolerability and dosing convenience compared to first-generation thiol therapies, with controlled release of cysteamine [6].

Group 1: Market Overview - As of December 30, 2025, two stocks in the energy sector are signaling potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] Group 2: Tetra Technologies Inc - Tetra Technologies (NYSE: TTI) has an RSI value of 70.7, indicating it is nearing overbought territory [6] - The stock has gained approximately 22% over the past month, reaching a 52-week high of $9.53 [6] - CJS Securities analyst Jonathan Tanwanteng initiated coverage on Tetra Technologies with an Outperform rating and a price target of $11.5 [6] - The current price action shows shares rose 0.6% to close at $9.40 [6] - Tetra Technologies has a momentum score of 98.37 and a value score of 69.30 [6] Group 3: Gulf Island Fabrication Inc - Gulf Island Fabrication (NASDAQ: GIFI) reported mixed third-quarter results, with revenue of $51.5 million and adjusted EBITDA of $2.5 million [6] - The company’s stock has increased around 14% over the past five days, with a 52-week high of $12.00 [6] - Gulf Island Fabrication has an RSI value of 84.9, indicating it is significantly overbought [6] - The stock closed at $11.94 on Monday [6]

Group 1: Market Overview - As of December 30, 2025, two stocks in the energy sector are signaling potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] Group 2: Tetra Technologies Inc - Tetra Technologies (NYSE: TTI) has an RSI value of 70.7, indicating it is nearing overbought territory [6] - The stock has gained approximately 22% over the past month, reaching a 52-week high of $9.53 [6] - CJS Securities analyst Jonathan Tanwanteng initiated coverage on Tetra Technologies with an Outperform rating and a price target of $11.5 [6] - The stock closed at $9.40, with a momentum score of 98.37 and a value score of 69.30 [6] Group 3: Gulf Island Fabrication Inc - Gulf Island Fabrication (NASDAQ: GIFI) reported mixed third-quarter results, with revenue of $51.5 million and adjusted EBITDA of $2.5 million [6] - The company’s stock has increased by around 14% over the past five days, achieving a 52-week high of $12.00 [6] - Gulf Island Fabrication has an RSI value of 84.9, indicating it is in overbought territory [6] - The stock closed at $11.94 on Monday [6]

Core Insights - TETRA Technologies, Inc. has signed a term sheet to form a joint venture with Magrathea Metals, Inc. to enhance the domestic magnesium metal supply chain in the U.S. [1][4] - Magnesium is recognized as a critical mineral essential for the defense industrial base and broader economy [2][6] Group 1: Joint Venture and Strategic Goals - The joint venture aims to rebuild America's magnesium metal defense industrial base at TETRA's Evergreen Project in Southwest Arkansas [1][4] - TETRA's ONE TETRA 2030 strategy focuses on clean and secure domestic manufacturing of critical minerals, including magnesium [4] - Magrathea has received Defense Production Act Title III funding to support its initial commercial phase at TETRA's Evergreen Plant [4] Group 2: Project Details - TETRA is constructing a bromine production facility projected to produce 75 million lbs. of bromine annually, with operations expected to start by the end of 2027 [3] - The Evergreen Project will also focus on producing lithium and magnesium from brine, leveraging Magrathea's innovative electrolytic magnesium technology [3][4] Group 3: Industry Context - The partnership is positioned to enhance the U.S. supply chain for magnesium, which is critical for national security and economic stability [2][6] - The collaboration is seen as a significant step towards ensuring that the U.S. can compete globally in the defense industry [4]

Group 1 - TETRA Technologies, Inc. will host one-on-one meetings with institutional investors on December 10, 2025, at the Wells Fargo 24th Annual Energy & Power Symposium in New York City [1] - The company focuses on environmentally conscious services and solutions across six continents, with a portfolio that includes Energy Services, Industrial Chemicals, and Critical Minerals [2] - TETRA is expanding into the low-carbon energy market, leveraging its chemistry expertise and global infrastructure to meet the demand for sustainable energy [2] Group 2 - TETRA Technologies announced strong third quarter 2025 financial results, indicating positive performance [4] - The company is undergoing a CFO transition with the planned retirement of Elijio Serrano and the appointment of Matt Sanderson [5]